 STAMFORD, Conn., July 20, 2021 GLOBE NEWSWIRE -- SpringWorks Therapeutics, Inc. Nasdaq: SWTX announced today that the United States Patent and Trademark Office USPTO has issued U.S. Patent No. 11,066,358 the 358 patent, directed to mirdametinib, the Companys product candidate in development for several oncology indications, including as a monotherapy for patients with neurofibromatosis type 1-associated plexiform neurofibromas NF1-PN. The 358 patent, assigned to Warner-Lambert Company LLC a subsidiary of Pfizer, expires in 2041. The 358 patent is a composition of matter patent that covers the polymorphic form of mirdametinib that is currently in clinical development. SpringWorks has exclusive rights to the 358 patent pursuant to an existing worldwide license with Pfizer. 